Abstract
The introduction of exogenous wild-type p53 into human cancer cells bearing p53 mutation does not necessarily result in inhibition of tumor growth. We have demonstrated this in MDA-MB468 breast cancer cells which are hemizygous for p53 mutation and also in KM12SM colorectal carcinoma cells which are heterozygous for p53 mutation. The wtp53 transfectants decreased three- to four-fold the number of colonies compared with controls. Most wtp53-expressing cells died by apoptosis at early passages, but some cells were able to form colonies and their proliferation rate was similar to control transfectants. This reversion was observed in three of the six MDA-MB-468 clones selected. When MDA-wtp53 transfectants were implanted orthotopically in nude mice only one clone showed prolonged tumor latency. No differences were found in either tumor proliferation or apoptosis in tumors. Integration and expression of exogenous wtp53 was assessed in early and late passages in vitro, and in tumors growing in vivo. Consistently, we found mutations in the exogenous wtp53 gene of MDA-MB468 transfectants. Excision of the exogenous gene was an alternative to abrogate the wtp53 function that was extremely efficient in KM12 cells, although they maintained resistance to geneticin. These results were corroborated by the functional assay in yeast. In conclusion, wtp53 is inactivated in these cancer cells by different mechanisms. The presence of mutated p53 may confer genome instability and mutator ability, which allows cells to escape the effects of the exogenous wtp53 and contributes to the failure of wtp53 gene therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Greenblatt MS, Bennett WP, Hollstein M, Harris CC . Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res 1994 54: 4855–4878
Sidransky D, Hollstein M . Clinical implications of the p53 gene Annu Rev Med 1996 47: 285–301
Finlay CA . The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth Mol Cel Biol 1993 13: 301–306
Knippschild U, Oren M, Deppert W . Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion Oncogene 1996 12: 1755–1765
Farmer G et al. Wild-type p53 activates transcription in vitro Nature 1992 358: 83–86
Arrowsmith CH, Morin P . New insights into p53 function from structural studies Oncogene 1996 12: 1379–1385
Buckbinder L, Talbott R, Seizinger BR, Kley N . Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes Proc Natl Acad Sci USA 1994 91: 10640–10644
Canman CE, Chen CY, Lee MH, Kastan MB . DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis Cold Spring Harbor Symposia on Quantitative Biology 1994 59: 277–286
Kastan MB, Canman CE, Leonard CJ . p53, cell cycle control and apoptosis: implications for cancer Cancer Metast Rev 1995 14: 3–15
Pollock RE et al. Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells Oncogene 1996 12: 2035–2039
Symonds H et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo Cell 1994 78: 703–711
Donehower LA . Effects of p53 mutation on tumor progression: recent insights from mouse tumor models Biochim Biophys Acta – Rev Cancer 1996 1242: 171–176
Ullrich SJ, Anderson CW, Mercer WE, Appella E . The p53 tumor suppressor protein, a modulator of cell proliferation J Biol Chem 1992 267: 15259–15262
Marchetti A et al. P53 mutations and histological type of invasive breast carcinoma Cancer Res 1993 53: 4665–4669
Casey G et al. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene Oncogene 1991 6: 1791–1797
Bacchetti S, Graham FL . Inhibition of cell proliferation by an adenovirus vector expression the human wild type p53 protein Int J Oncol 1993 3: 781–788
Merlo GR et al. Growth suppression of normal mammary epithelial cells by wild-type p53. Breast Cancer: from Biology to Therapy Ann NY Acad Sci 1993 689: 108–113
Merlo GR et al. Growth suppression of normal mammary epithelial cells by wild-type p53 Oncogene 1994 9: 443–453
Cirielli C et al. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo Int J Cancer 1995 63: 673–679
Wang YS et al. Reconstitution of wild-type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus-induced T-cell lymphoma line Cell Growth Differ 1993 4: 467–473
Roemer K, Friedmann T . Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function. Gene Therapy for Neoplastic Diseases Ann NY Acad Sci 1994 716: 265–282
Shaw P et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line Proc Natl Acad Sci USA 1992 89: 4495–4499
Liu TJ et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck Cancer Res 1995 55: 3117–3122
Yang CL, Cirielli C, Capogrossi MC, Passaniti A . Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells Cancer Res 1995 55: 4210–4213
Radinsky R et al. Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53 Oncogene 1994 9: 1877–1883
Cajot JF et al. Growth suppression mediated by transfection of p53 in Hut292DM human lung cancer cells expressing endogenous wild-type p53 protein Cancer Res 1992 52: 6956–6960
Noble JR et al. Effects of exogenous wild-type-p53 on a human lung carcinoma cell line with endogenous wild-type-p53 Exp Cell Res 1992 203: 297–304
Chen YM et al. Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate Oncogene 1991 6: 1799–1805
Brenner L et al. Wild-type p53 tumor suppressor gene restores differentiation of human squamous carcinoma cells but not the response to transforming growth factor-beta Cell Growth Differ 1993 4: 993–1004
Soddu S et al. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells Blood 1994 83: 2230–2237
Lee JM, Bernstein A . Apoptosis, cancer and the p53 tumour suppressor gene Cancer Metastas Rev 1995 14: 149–161
Vojtesek B, Lane DP . Regulation of p53 protein expression in human breast cancer cell lines J Cell Sci 1993 105: 607–612
Callahan R . p53 Mutations, another breast cancer prognostic factor J Natl Cancer Inst 1992 84: 826–827
Lane DP . p53 and human cancers Br Med Bull J 1994 50: 582–599
Tlsty TD et al. Genomic integrity and the genetics of cancer Cold Spring Harbor Symposia on Quantitative Biology 1994 59: 265–275
Coleman WB, Tsongalis GJ . Multiple mechanisms account for genomic instability and molecular mutation in neoplastic transformation Clin Chem 1995 41: 644–657
Pietenpol JA et al. Mammalian cells resistant to tumor suppressor genes Proc Natl Acad Sci USA 1996 93: 8390–8394
Kyo E et al. Reduced tumorigenicity and cell motility of a gastric carcinoma cell line by introduction of wild-type p53 gene Int J Oncol 1993 3: 265–271
Roth JA et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer Nature Med 1996 2: 985–991
Harris CC . Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies J Natl Cancer Inst 1996 88: 1442–1455
Wigler M et al. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells Cell 1977 16: 777–785
Schmidt-Kastner PK, Jardine K, Cormier M, McBurney MW . Genes transfected into embryonal carcinoma stem cells are both lost and inactivated at high frequency Somat Cell Mole Genet 1996 22: 383–392
Carder PJ et al. Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma Br J Cancer 1995 71: 215–218
Usmani BA, Lunec J, Sherbet GV . DNA repair and repair fidelity in metastatic variants of the B16 murine melanoma J Cell Biochem 1993 51: 336–344
Valgardsdottir R et al. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis APMIS 1997 105: 121–130
Zhang W, Shay JW, Deisseroth A . Inactive p53 mutants may enhance the transcriptional activity of wild-type p53 Cancer Res 1993 53: 4772–4775
Milner J, Metcalf EA . Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation Cell 1991 65: 765–774
Levine AJ . 11th Klenk, Ernst Lecture – the p53 tumor suppressor gene and product Biological Chemistry Hoppe–Seyler 1993 374: 227–235
Kern SE et al. Oncogenic forms of p53 inhibit p53-regulated gene expression Science 1992 256: 827–830
Kimura M et al. Inability to induce the alteration of tumorigenicity and chemosensitivity of p53-null human pancreatic carcinoma cells after the transduction of wild-type p53 gene Anticancer Res 1997 17: 879–884
Peinado MA, Malkhosyan S, Velazquez A, Perucho M . Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction Proc Natl Acad Sci USA 1992 89: 10065–10069
Hartwell L, Weinert T, Kadyk L, Garvik B . Cell cycle checkpoints, genomic integrity, and cancer Cold Spring Harbor Symposia on Quantitative Biology 1994 59: 259–263
Bertrand P et al. Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein Oncogene 1997 14: 1117–1122
Lesoon-Wood LA et al. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice Hum Gene Ther 1995 6: 395–405
Flaman JM et al. A simple p53 functional assay for screening cell lines, blood, and tumors Proc Natl Acad Sci USA 1995 92: 3963–3967
Skenan P et al. New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 1990 82: 1107–1112
Bonfil RD et al. Stimulation of angiogenesis as an explanation of matrigel-enhanced tumorigenicity Int J Cancer 1994 58: 233–239
Mollinedo F, Martinez-Dalmau R, Modolell M . Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH3 Biochem Biophys Res Commun 1993 192: 603–609
Gavrieli Y, Sherman Y, Ben-Sasson SA . Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation J Cell Biol 1992 119: 493–501
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vinyals, A., Peinado, M., Gonzalez-Garrigues, M. et al. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein. Gene Ther 6, 22–33 (1999). https://doi.org/10.1038/sj.gt.3300786
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300786
Keywords
This article is cited by
-
Cyclin-dependent kinase 11p110 (CDK11p110) is crucial for human breast cancer cell proliferation and growth
Scientific Reports (2015)
-
Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells
Molecular Biology Reports (2013)
-
A novel approach to cancer treatment using structural hybrids of the p53 gene family
Cancer Gene Therapy (2012)
-
p53 Binds to Estrogen Receptor 1 Promoter in Human Breast Cancer Cells
Pathology & Oncology Research (2012)
-
Limited importance of the dominant-negative effect of TP53missense mutations
BMC Cancer (2011)